Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Jeffrey John Popma, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Jeffrey Popma and Donald Cutlip.
Jeffrey Popma
Connection Strength
1.470
Donald Cutlip
  1. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC Cardiovasc Interv. 2017 01 23; 10(2):160-167.
    View in: PubMed
    Score: 0.169
  2. In-hospital and nine-month outcomes among patients with coronary lesions involving a side branch and treated with bare metal stents. Catheter Cardiovasc Interv. 2010 Dec 01; 76(7):951-7.
    View in: PubMed
    Score: 0.110
  3. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol. 2004 Sep 15; 44(6):1210-4.
    View in: PubMed
    Score: 0.072
  4. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002 Dec 18; 40(12):2082-9.
    View in: PubMed
    Score: 0.063
  5. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001 Apr 17; 103(15):1967-71.
    View in: PubMed
    Score: 0.056
  6. Coronary artery stenting in the aged. J Am Coll Cardiol. 2001 Mar 01; 37(3):856-62.
    View in: PubMed
    Score: 0.056
  7. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol. 1999 Sep; 34(3):698-706.
    View in: PubMed
    Score: 0.050
  8. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J. 2018 05 14; 39(19):1687-1697.
    View in: PubMed
    Score: 0.046
  9. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol. 2017 Feb 14; 69(6):679-691.
    View in: PubMed
    Score: 0.042
  10. Carotid angiographic characteristics in the CREST trial were major contributors to periprocedural stroke and death differences between carotid artery stenting and carotid endarterectomy. J Vasc Surg. 2016 Apr; 63(4):851-7, 858.e1.
    View in: PubMed
    Score: 0.039
  11. A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial. Int J Cardiol. 2012 May 17; 157(1):96-101.
    View in: PubMed
    Score: 0.029
  12. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011 Apr 26; 57(17):1778-83.
    View in: PubMed
    Score: 0.028
  13. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011 Jan 18; 57(3):253-69.
    View in: PubMed
    Score: 0.028
  14. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011 Jan; 32(2):205-17.
    View in: PubMed
    Score: 0.028
  15. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). Am J Cardiol. 2010 Nov 15; 106(10):1436-42.
    View in: PubMed
    Score: 0.027
  16. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010 Jul 01; 363(1):11-23.
    View in: PubMed
    Score: 0.027
  17. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010 Feb 09; 55(6):543-54.
    View in: PubMed
    Score: 0.026
  18. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009 Dec; 2(12):1208-18.
    View in: PubMed
    Score: 0.026
  19. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009 Oct; 2(10):977-85.
    View in: PubMed
    Score: 0.025
  20. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009 Apr 28; 53(17):1488-97.
    View in: PubMed
    Score: 0.025
  21. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv. 2008 Oct; 1(5):524-32.
    View in: PubMed
    Score: 0.024
  22. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008 Jun; 1(3):248-57.
    View in: PubMed
    Score: 0.023
  23. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12; 117(6):790-7.
    View in: PubMed
    Score: 0.023
  24. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007 Nov 27; 50(22):2111-6.
    View in: PubMed
    Score: 0.022
  25. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol. 2007 Oct 22; 100(8B):56M-61M.
    View in: PubMed
    Score: 0.022
  26. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007 Sep 01; 100(5):818-23.
    View in: PubMed
    Score: 0.022
  27. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007 May; 3(1):50-3.
    View in: PubMed
    Score: 0.021
  28. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention. 2006 Aug; 2(2):161-8.
    View in: PubMed
    Score: 0.020
  29. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006 Jul 04; 48(1):32-6.
    View in: PubMed
    Score: 0.020
  30. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2005 Aug; 1(2):157-64.
    View in: PubMed
    Score: 0.019
  31. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005 May 15; 95(10):1140-5.
    View in: PubMed
    Score: 0.019
  32. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol. 2005 Jan 15; 95(2):173-7.
    View in: PubMed
    Score: 0.018
  33. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004 Oct 07; 351(15):1493-501.
    View in: PubMed
    Score: 0.018
  34. Utility of the Safe-Cross-guided radiofrequency total occlusion crossing system in chronic coronary total occlusions (results from the Guided Radio Frequency Energy Ablation of Total Occlusions Registry Study). Am J Cardiol. 2004 Oct 01; 94(7):853-8.
    View in: PubMed
    Score: 0.018
  35. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol. 2004 Jun 01; 93(11):1340-6, A5.
    View in: PubMed
    Score: 0.018
  36. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004 Feb 10; 109(5):634-40.
    View in: PubMed
    Score: 0.017
  37. Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv. 2003 Nov; 60(3):344-51.
    View in: PubMed
    Score: 0.017
  38. Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J. 2003 May; 145(5):847-54.
    View in: PubMed
    Score: 0.016
  39. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15; 90(10):1079-83.
    View in: PubMed
    Score: 0.016
  40. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002 Mar 19; 105(11):1285-90.
    View in: PubMed
    Score: 0.015
  41. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation. 2001 Aug 14; 104(7):773-8.
    View in: PubMed
    Score: 0.014
  42. Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15; 87(2):152-6.
    View in: PubMed
    Score: 0.014
  43. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001 Jan 15; 87(2):157-62.
    View in: PubMed
    Score: 0.014
  44. Comparative analysis of early and late angiographic outcomes using two quantitative algorithms in the Balloon versus Optimal Atherectomy Trial (BOAT). Am J Cardiol. 1999 Jun 15; 83(12):1611-6.
    View in: PubMed
    Score: 0.012
  45. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 03; 339(23):1665-71.
    View in: PubMed
    Score: 0.012
  46. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) Circulation. 1998 Feb 03; 97(4):322-31.
    View in: PubMed
    Score: 0.011
  47. 'Optimal' directional coronary atherectomy: final results of the Optimal Atherectomy Restenosis Study (OARS). Circulation. 1998 Feb 03; 97(4):332-9.
    View in: PubMed
    Score: 0.011
  48. Quantitative coronary angiographic and intravascular ultrasound assessment of a new nonarticulated stent: report from the Advanced Cardiovascular Systems MultiLink stent pilot study. J Am Coll Cardiol. 1998 Jan; 31(1):50-6.
    View in: PubMed
    Score: 0.011
  49. Acute results of directional coronary atherectomy in the Balloon Versus Optimal Atherectomy Trial (BOAT) pilot phase. Coron Artery Dis. 1996 Apr; 7(4):290-3.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.